These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 34791506)

  • 1. CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.
    Li L; Hu Y; Chen D; Zhu J; Bao W; Xu X; Chen H; Chen W; Feng R
    Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34791506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo.
    Xiao Y; Yuan Y; Zhang Y; Li J; Liu Z; Zhang X; Sheng Z; Xu T; Wang X
    Clin Transl Oncol; 2015 Jun; 17(6):431-7. PubMed ID: 25387568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and significance of CMTM5 and epidermal growth factor receptor in prostate cancer].
    Yuan YQ; Zhang YX; Liu ZH; Qin CP; Sheng ZZ; Xu T; Wang XF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Aug; 47(4):571-6. PubMed ID: 26284387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CMTM5 inhibits the tumor cell behavior of prostate cancer by downregulation of HER2].
    Xu T; Li J; Xiao YB; Liu ZH; Li Q; Wang XF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 42(4):386-90. PubMed ID: 20721248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulation of miR-10b-3p promotes the progression of hepatocellular carcinoma cells via targeting CMTM5.
    Guan L; Ji D; Liang N; Li S; Sun B
    J Cell Mol Med; 2018 Jul; 22(7):3434-3441. PubMed ID: 29691981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells.
    Yuan Y; Sheng Z; Liu Z; Zhang X; Xiao Y; Xie J; Zhang Y; Xu T
    J Cancer; 2020; 11(13):3762-3770. PubMed ID: 32328181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.
    Zheng J; Liu C; Shi J; Wen K; Wang X
    Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microrchidia family CW‑type zinc finger 2 promotes the proliferation, invasion, migration and epithelial‑mesenchymal transition of glioma by regulating PTEN/PI3K/AKT signaling via binding to N‑myc downstream regulated gene 1 promoter.
    Zhang J; Yang Y; Dong Y; Liu C
    Int J Mol Med; 2022 Feb; 49(2):. PubMed ID: 34913078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA RHPN1-AS1 inhibition induces autophagy and apoptosis in prostate cancer cells via the miR-7-5p/EGFR/PI3K/AKT/mTOR signaling pathway.
    Ma X; Ren H; Zhang Y; Wang B; Ma H
    Environ Toxicol; 2022 Dec; 37(12):3013-3027. PubMed ID: 36125241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer.
    Ma T; Chen H; Wang P; Yang N; Bao J
    Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162
    [No Abstract]   [Full Text] [Related]  

  • 11. Hsa_circ_0030586 promotes epithelial-mesenchymal transition in prostate cancer via PI3K-AKT signaling.
    Luo GC; Chen L; Fang J; Yan ZJ
    Bioengineered; 2021 Dec; 12(2):11089-11107. PubMed ID: 34852706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSMC4 promotes prostate carcinoma progression by regulating the CBX3-EGFR-PI3K-AKT-mTOR pathway.
    Liu K; Zhang S; Gong Y; Zhu P; Shen W; Zhang Q
    J Cell Mol Med; 2023 Aug; 27(16):2437-2447. PubMed ID: 37436074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of polyethylenimine-functionalized gold nanoclusters carrying plasmid CMTM5 in impeding the malignant progression of prostate cancer cells by promoting EGFR endocytosis.
    Li L; Li C; Miao F; Chen W; Kong X; Ye R; Feng R
    Neoplasma; 2024 Feb; 71(1):48-59. PubMed ID: 38295104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research advances in CKLF-like MARVEL transmembrane domain containing member 5].
    Yuan YQ; Xiao YB; Liu ZH; Zhang XW; Xu T; Wang XF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Dec; 34(6):625-8. PubMed ID: 23286412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inhibitory effect of CMTM5 on xenografted human prostatic cancer in nude mice].
    Xiao YB; Xie J; Zhang GX; Li J; Hao YC; Zhang XW; Liu ZH; Xu T; Wang XF
    Zhonghua Nan Ke Xue; 2012 Mar; 18(3):195-9. PubMed ID: 22474980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
    Yan G; Ru Y; Wu K; Yan F; Wang Q; Wang J; Pan T; Zhang M; Han H; Li X; Zou L
    Prostate; 2018 Feb; 78(3):166-177. PubMed ID: 29181846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EHMT2 promotes the development of prostate cancer by inhibiting PI3K/AKT/mTOR pathway.
    Fan HT; Shi YY; Lin Y; Yang XP
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7808-7815. PubMed ID: 31599405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/PI3K/AKT/mTOR signaling.
    Ding X; Xu X; He XF; Yuan Y; Chen C; Shen XY; Su S; Chen Z; Xu ST; Huang YH
    Bioengineered; 2021 Dec; 12(1):803-814. PubMed ID: 33648424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMTM5 exhibits tumor suppressor activity through promoter methylation in oral squamous cell carcinoma.
    Zhang H; Nan X; Li X; Chen Y; Zhang J; Sun L; Han W; Li T
    Biochem Biophys Res Commun; 2014 May; 447(2):304-10. PubMed ID: 24721428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer cell-derived extracellular vesicles transfer miR-182-5p and promote breast carcinogenesis via the CMTM7/EGFR/AKT axis.
    Lu C; Zhao Y; Wang J; Shi W; Dong F; Xin Y; Zhao X; Liu C
    Mol Med; 2021 Jul; 27(1):78. PubMed ID: 34294040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.